Advanced cell therapy with low tissue factor loaded product NestaCell® does not confer thrombogenic risk for critically ill COVID-19 heparin-treated patients.
Biomed Pharmacother
; 149: 112920, 2022 May.
Article
in En
| MEDLINE
| ID: mdl-36068779
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Thromboplastin
/
COVID-19
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Biomed Pharmacother
Year:
2022
Type:
Article